Meyer Benjamen M, Campos Jessica K, Collard de Beaufort Jonathan C, Chen Ivette, Khan Muhammad Waqas, Amin Gizal, Zarrin David A, Lien Brian V, Coon Alexander L
College of Medicine, University of Arizona, Tucson, AZ 85724, USA.
Department of Neurological Surgery, University of California Irvine, Orange, CA 92868, USA.
Biomedicines. 2023 Aug 9;11(8):2234. doi: 10.3390/biomedicines11082234.
The use of periprocedural dual antiplatelet therapy (DAPT) has significantly evolved along with innovations in the endovascular management of intracranial aneurysms. Historically, aspirin and clopidogrel have been the most commonly employed regimen due to its safety and efficacy. However, recent studies highlight the importance of tailoring DAPT regimens to individual patient characteristics which may affect clopidogrel metabolism, such as genetic polymorphisms. In the present report, a systematic review of the literature was performed to determine optimal antiplatelet use with flow diverting stents, intracranial stents, intrasaccular devices, and stent-assisted coiling. Studies were analyzed for the number of aneurysms treated, DAPT regimen, and any thromboembolic complications. Based on inclusion criteria, 368 studies were selected, which revealed the increasing popularity of alternative DAPT regimens with the aforementioned devices. Thromboembolic or hemorrhagic complications associated with antiplatelet medications were similar across all medications. DAPT with ticagrelor, tirofiban, or prasugrel are effective and safe alternatives to clopidogrel and do not require enzymatic activation. Further clinical trials are needed to evaluate different antiplatelet regimens with various devices to establish highest-level evidence-based guidelines and recommendations.
随着颅内动脉瘤血管内治疗技术的创新,围手术期双重抗血小板治疗(DAPT)的应用也有了显著发展。从历史上看,阿司匹林和氯吡格雷因其安全性和有效性,一直是最常用的治疗方案。然而,最近的研究强调了根据个体患者特征调整DAPT方案的重要性,这些特征可能会影响氯吡格雷的代谢,如基因多态性。在本报告中,我们对文献进行了系统回顾,以确定在使用血流导向支架、颅内支架、囊内装置和支架辅助弹簧圈栓塞时的最佳抗血小板治疗方案。分析了各项研究中治疗的动脉瘤数量、DAPT方案以及任何血栓栓塞并发症。根据纳入标准,选择了368项研究,这些研究表明上述装置使用替代DAPT方案的情况越来越普遍。所有药物中与抗血小板药物相关的血栓栓塞或出血并发症相似。替格瑞洛、替罗非班或普拉格雷的DAPT是氯吡格雷有效且安全的替代方案,且无需酶促激活。需要进一步的临床试验来评估不同装置使用不同抗血小板方案的情况,以建立最高水平的循证指南和建议。